CN116687956A - Medical hyaluronic acid skin repair liquid - Google Patents
Medical hyaluronic acid skin repair liquid Download PDFInfo
- Publication number
- CN116687956A CN116687956A CN202310710831.7A CN202310710831A CN116687956A CN 116687956 A CN116687956 A CN 116687956A CN 202310710831 A CN202310710831 A CN 202310710831A CN 116687956 A CN116687956 A CN 116687956A
- Authority
- CN
- China
- Prior art keywords
- parts
- prepared
- weight
- following components
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 27
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 27
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 27
- 239000007788 liquid Substances 0.000 title claims abstract description 27
- 230000008439 repair process Effects 0.000 title claims abstract description 26
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 16
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 16
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 14
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960001631 carbomer Drugs 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims abstract description 13
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000009972 noncorrosive effect Effects 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 229960004418 trolamine Drugs 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 27
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 4
- 206010015150 Erythema Diseases 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract description 4
- 206010040844 Skin exfoliation Diseases 0.000 abstract description 4
- 206010000496 acne Diseases 0.000 abstract description 4
- 230000035618 desquamation Effects 0.000 abstract description 4
- 231100000321 erythema Toxicity 0.000 abstract description 4
- 230000000474 nursing effect Effects 0.000 abstract description 4
- 239000011241 protective layer Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 208000010668 atopic eczema Diseases 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010012435 Dermatitis and eczema Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229960002744 mometasone furoate Drugs 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010058898 Hand dermatitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The application belongs to the technical field of biological medicine, and in particular relates to medical hyaluronic acid skin repair liquid which comprises glycerol, sodium hyaluronate solution, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific matching proportion of a formula: the glycerol is prepared from the following components in parts by weight: 3-5 parts; the sodium hyaluronate solution is prepared from the following components in parts by weight: 1-3 parts; the carbomer is prepared from the following components in parts by weight: 3-5 parts; the triethanolamine is prepared from the following components in parts by weight: 3-5 parts; the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts; the skin care product has reasonable structure, and forms a protective layer on the surface of skin in the use process, so as to relieve erythema, pruritus, stinging, fever, dryness and desquamation symptoms caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
Description
Technical Field
The application relates to the technical field of biological medicines, in particular to medical hyaluronic acid skin repair liquid.
Background
Dermatitis is a more common clinical disease, and is classified into contact dermatitis, eczema, allergic dermatitis and other types of dermatitis according to the dermatitis classification recommended by the world allergic organization. Among them, eczema which can be further classified among contact dermatitis (cosmetics, diapers, dermatitis lacquer) caused by contact with foreign substances, such as atopic dermatitis, seborrheic dermatitis, stasis dermatitis, self-sensitive dermatitis, periwound infectious dermatitis, eczema, chronic lichen simplex, tinea mycosis, hand dermatitis, polymorphous light eruption, etc.; eczema which cannot be further classified is perianal eczema, calf eczema, scrotum eczema, breast eczema, external ear eczema, spring eczema, summer eczema, prurigo and the like.
Dermatitis and eczema are often used synonymously to refer to an inflammation of the skin, representing the allergic reaction of the skin to chemicals, proteins, bacteria and fungi.
At present, most of the dermatitis therapeutic drugs mainly used by Western medicine are corticosteroids, and antihistamines and antibiotics are taken orally, wherein the antihistamines mainly play a role in relieving static itching, the antibiotics are used for treating infected skin lesions, and the external application of the corticosteroids-containing drugs is remarkable in treating the mild dermatitis. However, in recent years, skin damage caused by external hormone preparations has increased dramatically, and adverse reactions have become remarkable, which has become a social problem of great concern. If the corticosteroid-containing drugs are used frequently or in large amounts for a long period of time, they are susceptible to skin that is sensitive and may be accompanied by systemic skin sensitivity; the hormone can be absorbed into blood circulation through skin for a long time and a large amount of external use, thereby causing diabetes and the like; abuse of antibiotics may result in enhanced bacterial resistance and reduced immune function, resulting in repeated and difficult recovery.
For this reason, chinese patent document CN103006686a discloses a functional preparation for adjuvant therapy of atopic dermatitis and a preparation method thereof, which comprises the following raw materials by weight: 0.2 to 1 part of sodium hyaluronate, 5 to 10 parts of emulsifying thickener and 5 to 10 parts of grease, and deionized water is added to 100 parts. The patent document is a functional preparation containing sodium hyaluronate, and the combination of mometasone furoate emulsifiable paste can obviously improve the symptoms of dry eczema, can effectively restore the skin barrier function, reduce recurrence, and has better curative effect than single mometasone furoate emulsifiable paste; can be used for adjuvant treatment of dermatitis and eczema, with good therapeutic effect and safety, and reduced recurrence. However, this technique has an adjuvant therapeutic effect only on atopic dermatitis, and is not universal.
Based on the above, we propose a medical hyaluronic acid skin repair liquid.
Disclosure of Invention
This section is intended to outline some aspects of embodiments of the application and to briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section as well as in the description of the application and in the title of the application, which may not be used to limit the scope of the application.
The present application has been made in view of the problems occurring in the prior art.
Therefore, the application aims to provide the medical hyaluronic acid skin repair liquid, which can form a protective layer on the surface of skin in the using process and is used for relieving erythema, pruritus, stinging, fever and dry desquamation symptoms caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
In order to solve the technical problems, according to one aspect of the present application, the following technical solutions are provided:
the medical hyaluronic acid skin repair liquid comprises glycerin, sodium hyaluronate solution, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of the formula:
wherein,,
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the sodium hyaluronate solution is prepared from the following components in parts by weight: 1-3 parts;
the carbomer is prepared from the following components in parts by weight: 3-5 parts;
the triethanolamine is prepared from the following components in parts by weight: 3-5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
As a preferred embodiment of the medical hyaluronic acid skin repair liquid of the present application, wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and sub-packaging the mixture into medical glass bottles to obtain the medical hyaluronic acid skin repair liquid.
As a preferred embodiment of the medical hyaluronic acid skin repair liquid of the present application, wherein: the medical hyaluronic acid skin repair liquid has a model specification of 1.1mL, 1.15mL, 1.2mL, 1.25mL, 1.3mL, 1.4mL, 1.5mL, 1.6mL, 1.8mL, 2mL, 2.5mL, 3mL, 3.5mL, 4mL, 4.5mL, 5mL, 6mL, 7mL, 8mL, 9mL, 10mL, 12mL, 15mL, 18mL, 20mL, 22mL, 25mL, 28mL, 30mL, 32mL, 35mL, 36mL, 38mL, 40mL, 42mL, 45mL, 48mL, 50mL, 55mL, 60mL, 65mL, 70mL, 80mL, 90mL, 100mL, 120mL, 125mL, 130mL, 150mL, 155mL, 160mL, 165mL, 170mL, 175mL, 180mL, 190mL, 200mL, 210mL, 220mL, 245mL, 250mL, 300mL, 350mL, 400mL, 500mL and 500 mL.
As a preferred embodiment of the medical hyaluronic acid skin repair liquid of the present application, wherein: the using method is as follows: the external application method comprises cleaning affected part skin, opening external package, taking out appropriate amount of product, directly applying on cleaned affected part skin, and applying uniformly for 2-3 times daily or according with doctor's advice.
As a preferred embodiment of the medical hyaluronic acid skin repair liquid of the present application, wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Compared with the prior art, the application has the beneficial effects that:
forming a protective layer on the skin surface for relieving symptoms of erythema, itching, stinging, fever, dryness and desquamation caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
Detailed Description
The following detailed description of the present application will provide further details in order to make the above-mentioned objects, features and advantages of the present application more comprehensible.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present application, but the present application may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present application is not limited to the specific embodiments disclosed below.
In order to make the objects, technical solutions and advantages of the present application more apparent, embodiments of the present application will be described in further detail below.
The application provides the following technical scheme: a medical hyaluronic acid skin repairing liquid is used for forming a protective layer on the surface of skin during the use process, and is used for relieving erythema, pruritus, stinging, fever and dry desquamation symptoms caused by skin inflammation; nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations;
example 1
The medical hyaluronic acid skin repair liquid comprises glycerin, sodium hyaluronate solution, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of the formula:
wherein,,
the glycerol is prepared from the following components in parts by weight: 3 parts;
the sodium hyaluronate solution is prepared from the following components in parts by weight: 1 part;
the carbomer is prepared from the following components in parts by weight: 3 parts;
the triethanolamine is prepared from the following components in parts by weight: 3 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1 part;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4 parts;
the hexanediol is prepared from the following components in parts by weight: 1 part;
the purified water is prepared from the following components in parts by weight: 50 parts.
Wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and sub-packaging the mixture into medical glass bottles to obtain the medical hyaluronic acid skin repair liquid.
Wherein: the medical hyaluronic acid skin repair liquid has a model specification of 1.1mL, 1.15mL, 1.2mL, 1.25mL, 1.3mL, 1.4mL, 1.5mL, 1.6mL, 1.8mL, 2mL, 2.5mL, 3mL, 3.5mL, 4mL, 4.5mL, 5mL, 6mL, 7mL, 8mL, 9mL, 10mL, 12mL, 15mL, 18mL, 20mL, 22mL, 25mL, 28mL, 30mL, 32mL, 35mL, 36mL, 38mL, 40mL, 42mL, 45mL, 48mL, 50mL, 55mL, 60mL, 65mL, 70mL, 80mL, 90mL, 100mL, 120mL, 125mL, 130mL, 150mL, 155mL, 160mL, 165mL, 170mL, 175mL, 180mL, 190mL, 200mL, 210mL, 220mL, 245mL, 250mL, 300mL, 350mL, 400mL, 500mL and 500 mL.
Wherein: the using method is as follows: the external application method comprises cleaning affected part skin, opening external package, taking out appropriate amount of product, directly applying on cleaned affected part skin, and applying uniformly for 2-3 times daily or according with doctor's advice.
Wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Example 2
The medical hyaluronic acid skin repair liquid comprises glycerin, sodium hyaluronate solution, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of the formula:
wherein,,
the glycerol is prepared from the following components in parts by weight: 5 parts;
the sodium hyaluronate solution is prepared from the following components in parts by weight: 3 parts;
the carbomer is prepared from the following components in parts by weight: 5 parts;
the triethanolamine is prepared from the following components in parts by weight: 5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 6 parts;
the hexanediol is prepared from the following components in parts by weight: 2 parts;
the purified water is prepared from the following components in parts by weight: 100 parts.
Wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and sub-packaging the mixture into medical glass bottles to obtain the medical hyaluronic acid skin repair liquid.
Wherein: the medical hyaluronic acid skin repair liquid has a model specification of 1.1mL, 1.15mL, 1.2mL, 1.25mL, 1.3mL, 1.4mL, 1.5mL, 1.6mL, 1.8mL, 2mL, 2.5mL, 3mL, 3.5mL, 4mL, 4.5mL, 5mL, 6mL, 7mL, 8mL, 9mL, 10mL, 12mL, 15mL, 18mL, 20mL, 22mL, 25mL, 28mL, 30mL, 32mL, 35mL, 36mL, 38mL, 40mL, 42mL, 45mL, 48mL, 50mL, 55mL, 60mL, 65mL, 70mL, 80mL, 90mL, 100mL, 120mL, 125mL, 130mL, 150mL, 155mL, 160mL, 165mL, 170mL, 175mL, 180mL, 190mL, 200mL, 210mL, 220mL, 245mL, 250mL, 300mL, 350mL, 400mL, 500mL and 500 mL.
Wherein: the using method is as follows: the external application method comprises cleaning affected part skin, opening external package, taking out appropriate amount of product, directly applying on cleaned affected part skin, and applying uniformly for 2-3 times daily or according with doctor's advice.
Wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Although the application has been described hereinabove with reference to embodiments, various modifications thereof may be made and equivalents may be substituted for elements thereof without departing from the scope of the application. In particular, the features of the disclosed embodiments may be combined with each other in any manner as long as there is no structural conflict, and the exhaustive description of these combinations is not given in this specification merely for the sake of omitting the descriptions and saving resources. Therefore, it is intended that the application not be limited to the particular embodiment disclosed, but that the application will include all embodiments falling within the scope of the appended claims.
Claims (5)
1. A medical hyaluronic acid skin repair liquid is characterized in that: comprises glycerol, sodium hyaluronate solution, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of the formula:
wherein,,
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the sodium hyaluronate solution is prepared from the following components in parts by weight: 1-3 parts;
the carbomer is prepared from the following components in parts by weight: 3-5 parts;
the triethanolamine is prepared from the following components in parts by weight: 3-5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
2. The medical hyaluronic acid skin repair liquid according to claim 1, characterized in that: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and sub-packaging the mixture into medical glass bottles to obtain the medical hyaluronic acid skin repair liquid.
3. A medical hyaluronic acid skin repair liquid according to claim 2, characterized in that: the medical hyaluronic acid skin repair liquid has a model specification of 1.1mL, 1.15mL, 1.2mL, 1.25mL, 1.3mL, 1.4mL, 1.5mL, 1.6mL, 1.8mL, 2mL, 2.5mL, 3mL, 3.5mL, 4mL, 4.5mL, 5mL, 6mL, 7mL, 8mL, 9mL, 10mL, 12mL, 15mL, 18mL, 20mL, 22mL, 25mL, 28mL, 30mL, 32mL, 35mL, 36mL, 38mL, 40mL, 42mL, 45mL, 48mL, 50mL, 55mL, 60mL, 65mL, 70mL, 80mL, 90mL, 100mL, 120mL, 125mL, 130mL, 150mL, 155mL, 160mL, 165mL, 170mL, 175mL, 180mL, 190mL, 200mL, 210mL, 220mL, 245mL, 250mL, 300mL, 350mL, 400mL, 500mL and 500 mL.
4. The medical hyaluronic acid skin repair liquid according to claim 1, characterized in that: the using method is as follows: the external application method comprises cleaning affected part skin, opening external package, taking out appropriate amount of product, directly applying on cleaned affected part skin, and applying uniformly for 2-3 times daily or according with doctor's advice.
5. The medical hyaluronic acid skin repair liquid according to claim 1, characterized in that: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310710831.7A CN116687956A (en) | 2023-06-15 | 2023-06-15 | Medical hyaluronic acid skin repair liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310710831.7A CN116687956A (en) | 2023-06-15 | 2023-06-15 | Medical hyaluronic acid skin repair liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116687956A true CN116687956A (en) | 2023-09-05 |
Family
ID=87828853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310710831.7A Pending CN116687956A (en) | 2023-06-15 | 2023-06-15 | Medical hyaluronic acid skin repair liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116687956A (en) |
-
2023
- 2023-06-15 CN CN202310710831.7A patent/CN116687956A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169018B1 (en) | Use of sulphated sugar species | |
| CN105392472B (en) | Topical compositions and methods of use thereof | |
| CN1032900C (en) | Metrohidazole formulations and therapeutical uses thereof | |
| Zaug et al. | Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview) | |
| JP2002530271A5 (en) | ||
| EP1455802B1 (en) | Uses of chitosan oligosaccharides | |
| WO2019223699A1 (en) | Biological polysaccharide for preventing and treating acne and steroid-dependent dermatitis and use thereof | |
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| US5658896A (en) | Pharmaceutical composition regulating function of a living body | |
| CN1171588C (en) | Method of treatment of seborrheic dermatitis | |
| Rubin et al. | Oral polymeric N-acetyl-D-glucosamine and osteoarthritis | |
| CN1302813C (en) | Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method | |
| CN116687956A (en) | Medical hyaluronic acid skin repair liquid | |
| KR0181763B1 (en) | External therapeutic composition for dermatitis | |
| CN116763813A (en) | Medical hyaluronic acid skin repair gel | |
| US6225356B1 (en) | Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea | |
| EP1737467B1 (en) | Composition for the treatment of skin conditions | |
| CN1660441A (en) | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method | |
| CN104771405A (en) | Compound terbinafine preparation and applications thereof | |
| CN108653304A (en) | A kind of pterostilbene nano-micelle external-use gel and preparation method thereof | |
| CN105106108A (en) | Supermolecule controlled/slow-release type salicylate formula and preparation technology thereof | |
| CN100563663C (en) | A kind of treatment skin purulent infection and antifungal medicine for external use | |
| CN110613808A (en) | Emulsion for reducing skin melanoma and preparation method and application thereof | |
| DK174560B1 (en) | Topical pharmaceutical compsns. - contg. sucralfate, for treating skin and mucosal disorders | |
| CN102302442B (en) | Allicin vaginal suppository and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |